Mots-C 10mg

MOTS-c 10mg is a synthetic research peptide intended exclusively for laboratory, analytical, and scientific applications.

MOTS-c, short for Mitochondrial Open Reading Frame of the 12S rRNA Type-c, is a mitochondria-derived peptide composed of 16 amino acids. Research literature describes MOTS-c as a mitochondrial signaling peptide that can participate in cellular responses to metabolic stress and influence nuclear gene-expression pathways in experimental models.

Laboratory research involving MOTS-c may include:

• Mitochondrial signaling research
• Cellular bioenergetics
• Metabolic pathway studies
• Mitochondrial-to-nuclear communication
• Cellular stress-response research
• Peptide characterization
• Molecular interaction studies
• Peptide stability analysis
• Analytical method development
• In-vitro and preclinical research models

Published studies have examined MOTS-c across metabolic, mitochondrial, and other biological research models. These findings remain preclinical or investigational and should not be interpreted as evidence that a MOTS-c research product is safe or effective for human use.

Product Information

• Product: MOTS-c
• Strength: 10mg
• Classification: Mitochondrial-derived research peptide
• Peptide Length: 16 amino acids
• Primary Research Area: Mitochondrial biology
• Secondary Research Area: Metabolic signaling
• Intended Setting: Laboratory, analytical, and scientific research
• Supplier: Peptides R US

Regulatory / Research Use Notice

This product is offered solely for legitimate laboratory, analytical, and scientific research purposes.

It is not intended for human or veterinary consumption or administration and is not intended to diagnose, treat, cure, mitigate, or prevent any disease or medical condition.

No dosage, injection, reconstitution-for-human-use, weight-management, performance-enhancement, therapeutic, or clinical instructions are provided or implied.

FDA currently states that it has not identified human exposure data for drug products containing MOTS-c administered by any route and that important safety information is lacking. FDA has also cited potential concerns relating to immunogenicity, peptide-related impurities, aggregation, and API characterization.

In its 2026 review, FDA further noted the lack of adequate safety and effectiveness information in humans and concluded that these factors weighed against adding MOTS-c-related bulk drug substances to the 503A Bulks List